Tesabio.ai uses artificial intelligence to discover small molecules that restore balance in disease-related microRNA networks. These networks help regulate how proteins are produced, making them a promising route to addressing complex disease biology. The company's platform has shown early validation in models of metastatic breast cancer and anemia. [1]
Founded by Sebastián Ortiz Chamorro, Diego Galeano and University of Pittsburgh scientist Afshin Beheshti, Tesabio.ai combines computational discovery with expertise in microRNA biology. The company emerged from stealth in 2025 with a pre-seed round led by GRIDX to advance its approach to developing new medicines. [2] [1]